{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:34:17Z","timestamp":1791988457518,"version":"4.4.0"},"reference-count":15,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T00:00:00Z","timestamp":1407974400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0104215","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T18:40:36Z","timestamp":1408041636000},"page":"e104215","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"umin000003580","registry":"10.18810\/umin-japan"}],"author":[{"given":"Yutaka","family":"Fujiwara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Chayahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Kiyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,8,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jpainsymman.2005.01.010","article-title":"Oxycodone","volume":"29","author":"E Kalso","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"ref2","unstructured":"National Cancer Center. Cancer statistics in Japan 2010."},{"key":"ref3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/clpt.1992.176","article-title":"Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer","volume":"52","author":"KP Leow","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","article-title":"The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects","volume":"33","author":"R Poyhia","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"ref5","first-page":"296","article-title":"Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain","volume":"80","author":"KP Leow","year":"1995","journal-title":"Anesth Analg"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/dmd.32.4.447","article-title":"Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes","volume":"32","author":"B Lalovic","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"B Lalovic","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/dmd.104.000216","article-title":"Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant","volume":"32","author":"RI Sanchez","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","article-title":"Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone","volume":"74","author":"JB McCrea","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00280-004-0946-3","article-title":"Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients","volume":"55","author":"P Nygren","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-006-0359-6","article-title":"Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients","volume":"59","author":"WJ Loos","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref12","unstructured":"Merck & Co I (2003) EMEND (aprepitant) capsules, for oral use. NJ, USA: Whitehouse Station."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","article-title":"Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe","volume":"74","author":"AK Majumdar","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pain.2007.09.027","article-title":"How different is oxycodone from morphine?","volume":"132","author":"E Kalso","year":"2007","journal-title":"Pain"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e60239","DOI":"10.1371\/journal.pone.0060239","article-title":"CYP2D6 genotype dependent oxycodone metabolism in postoperative patients","volume":"8","author":"UM Stamer","year":"2013","journal-title":"PLoS One"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0104215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T14:33:27Z","timestamp":1589034807000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0104215"}},"subtitle":[],"editor":[{"given":"Emanuel F.","family":"Petricoin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,14]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0104215","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,14]]}}}